Aiventrosp. z o.o.

Research and experimental development on biotechnology

KRS: NIP: REGON:

Overview

Status
Suspended
Registry date
2024-05-28
Share capital
5 000,00 PLN
Activity description

Aiventro is a company that provides target prediction software for drug discovery, utilizing an advanced AI solution based on a neural network model. This model predicts drug-target activity for small molecules against over 1000 protein targets, using data from the ChEMBL database. The software is designed to deliver performance that exceeds current industry standards.

Registered address
ul. Gospodarcza 26, 20-213 Lublin, Poland
Website
aiventro.comWebsite active
Email
Email address current
Electronic delivery address
AE:PL-83076-82673-RFHBH-30

Financials

Revenue history

Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.

Debt

No entries in the National Debtors Register (KRZ). No proceedings in KRZ

Public aid

PurposeGross amount
De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier)
$11,555

Tenders

No recorded participation in tenders.

Authorized Representatives

Michał Komorowski — Management Board Member
Piotr Mikołaj Setny — President of the Management Board

Manner of representation

Each member of the management board is authorized to make declarations on behalf of the company independently.

Ownership

OwnerSharesShare valueStake
Michał Komorowski (46)
50$675.3150%
Piotr Mikołaj Setny (51)
50$675.3150%

Beneficial owners

Person
Michał Komorowski (46)
Piotr Mikołaj Setny (51)

Competitors

Name
ArdigenS.A.
BiotechnaS.A.
Saventic Healthsp. z o.o.
AI Corelabsp. z o.o.
IntelliseqS.A.
Receptonsp. z o.o.
InventroS.A.
4cell TherapiesS.A.
AI4Isp. z o.o.
Oncotherics PolandS.A.

Change history

DateEvent
2026-01-01Business suspended
2024-05-28Entered in the register

FAQ

Last updated: 2026-07-09